Flaharty Asset Management LLC Buys Shares of 933 Abbott Laboratories $ABT

Flaharty Asset Management LLC bought a new stake in shares of Abbott Laboratories (NYSE:ABT) in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 933 shares of the healthcare product maker’s stock, valued at approximately $124,000.

Other large investors have also recently modified their holdings of the company. Hughes Financial Services LLC bought a new stake in shares of Abbott Laboratories during the 1st quarter valued at about $27,000. Abound Financial LLC bought a new stake in shares of Abbott Laboratories during the 1st quarter valued at about $28,000. Elequin Capital LP bought a new stake in shares of Abbott Laboratories during the 1st quarter valued at about $30,000. Wormser Freres Gestion bought a new stake in shares of Abbott Laboratories during the 4th quarter valued at about $32,000. Finally, JCIC Asset Management Inc. bought a new stake in shares of Abbott Laboratories during the 1st quarter valued at about $32,000. Institutional investors own 75.18% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have recently issued reports on ABT shares. Mizuho lifted their price target on Abbott Laboratories from $130.00 to $140.00 and gave the company a “neutral” rating in a research report on Wednesday, July 16th. Evercore ISI lifted their price target on Abbott Laboratories from $140.00 to $145.00 and gave the company an “outperform” rating in a research report on Tuesday, July 8th. Royal Bank Of Canada boosted their target price on Abbott Laboratories from $145.00 to $147.00 and gave the stock an “outperform” rating in a research report on Tuesday, July 15th. BTIG Research dropped their target price on Abbott Laboratories from $148.00 to $145.00 and set a “buy” rating for the company in a research report on Friday, July 18th. Finally, William Blair upgraded Abbott Laboratories to a “strong-buy” rating in a research report on Thursday, July 17th. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $144.47.

Insiders Place Their Bets

In related news, CFO Philip P. Boudreau sold 5,550 shares of the company’s stock in a transaction on Friday, August 8th. The stock was sold at an average price of $134.55, for a total value of $746,752.50. Following the sale, the chief financial officer directly owned 51,003 shares of the company’s stock, valued at $6,862,453.65. This represents a 9.81% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.46% of the stock is currently owned by insiders.

Abbott Laboratories Price Performance

Shares of Abbott Laboratories stock opened at $132.04 on Wednesday. The company has a debt-to-equity ratio of 0.25, a current ratio of 1.82 and a quick ratio of 1.30. Abbott Laboratories has a one year low of $110.86 and a one year high of $141.23. The stock has a market capitalization of $229.81 billion, a P/E ratio of 16.55, a price-to-earnings-growth ratio of 2.51 and a beta of 0.69. The business’s 50 day simple moving average is $130.52 and its two-hundred day simple moving average is $131.36.

Abbott Laboratories (NYSE:ABT) last posted its earnings results on Thursday, July 17th. The healthcare product maker reported $1.26 earnings per share (EPS) for the quarter, meeting the consensus estimate of $1.26. Abbott Laboratories had a return on equity of 18.32% and a net margin of 32.43%.The firm had revenue of $11.14 billion for the quarter, compared to analysts’ expectations of $11.01 billion. During the same period in the previous year, the firm earned $1.14 earnings per share. The business’s revenue was up 7.4% compared to the same quarter last year. Abbott Laboratories has set its FY 2025 guidance at 5.100-5.200 EPS. Q3 2025 guidance at 1.280-1.320 EPS. Analysts forecast that Abbott Laboratories will post 5.14 EPS for the current year.

Abbott Laboratories Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, August 15th. Investors of record on Tuesday, July 15th were paid a $0.59 dividend. This represents a $2.36 annualized dividend and a yield of 1.8%. The ex-dividend date of this dividend was Tuesday, July 15th. Abbott Laboratories’s dividend payout ratio is presently 29.57%.

Abbott Laboratories Company Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.